Journal of drugs in dermatology: JDD Impact Factor & Information

Publisher: Strategic Communication in Dermatology

Journal description

Current impact factor: 1.32

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 1.32
2012 Impact Factor 1.161
2011 Impact Factor 1.566
2010 Impact Factor 1.954

Impact factor over time

Impact factor
Year

Additional details

5-year impact 0.00
Cited half-life 4.10
Immediacy index 0.28
Eigenfactor 0.01
Article influence 0.00
Other titles Journal of drugs in dermatology (Online), JDD
ISSN 1545-9616
OCLC 60628032
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Human leukocyte antigen (HLA) antigens vary considerably in different racial groups, and an analysis of results from several geographical locations suggests that vitiligo appears to be associated with different HLA antigens in different groups. The aim of this work was to assess the association of HLA-Cw with vitiligo in the Egyptian population. Forty unrelated patients with nonsegmental vitiligo and 20 matched controls were selected. A polymerase chain reaction sequence specific primer (PCR-SSP) method was used to determine HLA DNA typing. There was a statistically significant difference in the association of HLA-Cw6 with vitiligo in the 2 studied groups. A comparatively increased number of patients showed HLA-Cw2 and HLA-Cw7 (13.64%). However, there were no statistically significant differences. To the best of our knowledge, this is the first molecular study of HLA typing in Egyptian patients with vitiligo. Our findings are in agreement with earlier studies that reported statistically increased frequencies for allele of HLA-Cw6 in Northern Italian, Kuwaiti, Chinese Han, and Saudi populations (45.45%, P <.05). J Drugs Dermatol . 2015;14(4):359-364.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):359-364.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Worldwide air pollution is a major health concern. There is accumulating scientific evidence that air pollution plays an important role in extrinsic aging. This article invites the reader to consider pollution as a possible emerging etiologic agent for the development of melasma. Pollution may be a risk factor for melasma and other facial pigmentary dyschromias. Air pollution in the form of airborne particulate matter (PM) and Polycyclic aromatic hydrocarbons (PAHs) enter the skin via nanoparticles and generate quinones, which are redox-cycling chemicals that produce reactive oxygen species (ROS). The PM increases the amount of ROS that triggers the increase of metalloproteinases that leads to extrinsic aging, which includes skin pigmentation. The incidence of disorders of facial hyperpigmentation specifically, melasma, is increased in persons of skin type III-VI living in India and South East Asia. Interestingly, these are also geographic regions with very heavy pollution. India, South East Asia, China, and United States lead the world in air pollution. J Drugs Dermatol . 2015;14(4):337-341.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):337-341.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Minocycline is among the most common drugs to cause drug-induced pigmentation. Dermal deposition of drug metabolites typically occurs in areas of vascular leakage, such as surrounding lower extremity spider veins, within erythema associated with solar elastosis, and in areas of bruising. The skin affected by minocycline pigmentation typically takes on a slate-gray coloring in affected areas. The current patient developed minocycline pigmentation after carbon dioxide laser resurfacing of her upper lip to treat rhytides in the laser-treated area. Laser treatment with the 1,064 nm, Q-switched Nd:YAG laser was able to remove the pigmentation. J Drugs Dermatol . 2015;14(4):411-414.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):411-414.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Facial dyspigmentation treatment is an unmet need in dermatology with increasing challenges due to the questionable safety of hydroquinone. This research examined a new OTC formulation containing hydroxyphenoxy propionic acid, ellagic acid, yeast extract, and salicylic acid on subjects who previously completed 12 weeks of treatment with 4% hydroquinone and 0.025% retinoic acid. The goal of this study was to evaluate the skin lightening and tolerability profile of a 20-week maintanence therapy with a cosmeceutical formulation during the summer months. 33 healthy subjects ages 25-60 years with moderate facial dyspigmentation defined as a score of 3 on a 5-point scale were enrolled. There was statistically significant improvement at week 20 in terms of even skin tone (P<0.001), spot intensity (P<0.001), spot size (P<0.05) and overall hyperpigmentation (P=0.002).
    Journal of drugs in dermatology: JDD 04/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate whether treatment differences exist in male and female patients with moderate to severe acne treated with clindamycin phosphate 1.2%/BP 3.75% gel or vehicle as monotherapy. METHODS: A post hoc analysis comparing the efficacy and cutaneous tolerability in 498 male and female patients with moderate to severe acne receiving clindamycin phosphate 1.2%/BP 3.75% gel, or vehicle for 12 weeks. RESULTS: The efficacy of clindamycin phosphate 1.2%/BP 3.75% gel was greater than vehicle ( P >.001) in both genders. Within the clindamycin phosphate 1.2%/BP 3.75% gel group, the mean percent change from baseline in inflammatory and noninflammatory lesion counts was greater among females than males, as was the percentage of subjects who achieved a 2-grade reduction in the EGSS ( P =.049). LIMITATIONS: It is not possible to determine the contributions of the individual active ingredients. CONCLUSIONS: Clindamycin phosphate 1.2%/BP 3.75% gel provides statistically significant greater efficacy than vehicle with a favorable safety and tolerability profile. It appears to be more effective in female patients. J Drugs Dermatol. 2015;14(4):381-384.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):381-384.
  • Journal of drugs in dermatology: JDD 04/2015; 14(4):332-334.
  • [Show abstract] [Hide abstract]
    ABSTRACT: First impressions are lasting, consequential and defined as the immediate judgment made of another from zero acquaintance. Multiple studies have reported the benefits of cosmetic make-up. We set out to investigate the psychosocial and aesthetic effects of cosmetic make-up in order to better understand why women wear it. MATERIALS AND METHODS: Twenty-seven women were recruited in order to examine the effects of cosmetic make-up on first impressions. The photographs of individual subjects wearing the control cosmetics, their own make-up, and no make-up were randomly assigned to three binders (A, B, and C). Three hundred evaluators participated (100 evaluators per book) and completed a 10-point First Impression Scale for each of the 27 photos in their binder. RESULTS: Statistical analysis of the collected data was conducted in SPSS using two-tailed t-tests to determine the statistical significance of the differences between first impressions of Own Make-up vs No Make-up, No Make-up vs Control Make-up, and Own Makeup vs Control Make-up. There was a significant difference in improvement in all pairings across all 8 categories in the First Impressions questionnaire particularly in perceived age between own make-up, no make-up, control make-up (41, 42, 38; P <0.001). DISCUSSION: Our study evaluated the first impressions, age perception, self-esteem, and the quality of life impact that cosmetic makeup has on women's appearance and confidence. Subjects wearing cosmetic make-up appeared 4 years younger than those wearing no make-up. And the control cosmetic make-up subjects on average projected a 37% better first impression than subjects wearing no make-up. We objectively quantified and qualified the benefits of applying cosmetic make-up. Make-up can reduce the perceived age, improve the first impression projected and increase the self-esteem of those who apply it. J Drugs Dermatol. 2015;14(4):366-374.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):366-374.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Facial dyspigmentation treatment is an unmet need in dermatology with increasing challenges due to the questionable safety of hydroquinone. This research examined a new OTC formulation containing hydroxyphenoxy propionic acid, ellagic acid, yeast extract, and salicylic acid on subjects who previously completed 12 weeks of treatment with 4% hydroquinone and 0.025% retinoic acid. The goal of this study was to evaluate the skin lightening and tolerability profile of a 20-week maintanence therapy with a cosmeceutical formulation during the summer months. 33 healthy subjects ages 25-60 years with moderate facial dyspigmentation defined as a score of 3 on a 5-point scale were enrolled. There was statistically significant improvement at week 20 in terms of even skin tone ( P <0.001), spot intensity ( P <0.001), spot size ( P <0.05) and overall hyperpigmentation ( P =0.002). J Drugs Dermatol . 2015;14(4):386-390.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):386-390.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Photosensitivity (PS) in cutaneous lupus erythematosus (CLE) contributes to decreased quality of life (QoL). AIMS: We aimed to assess baseline knowledge about sun protection in persons with CLE and identify knowledge differences by race. Additionally, we aimed to determine the impact of a verbal educational intervention on photoprotection and CLE. METHODS: 31 adults with CLE were recruited from an academic-based dermatology clinic and completed a 17-item questionnaire about CLE and sun protection at three time points: pre- intervention (PR-I), post-intervention (PO-I), and 3-month phone follow up (3MF). An educational intervention using American Academy of Dermatology CLE and sun protection education materials was delivered between PR-I and PO-I. RESULTS: 31 subjects participated at PR-I and PO-I, and 25 subjects (81%) at 3MF. Baseline CLE-related PS and photoprotection knowledge differed significantly by race, with non-Caucasians demonstrating less knowledge ( P = 0.049). Knowledge about sun exposure being linked to lupus increased from 81% to 97% ( P =0.25) between PR-I and PO-I. At PR-I, 19% agreed that smoking was linked to lupus compared to 90% PO-I ( P <0.001). There was increased knowledge of lupus risk for non-Caucasians, UV exposure indoors, and photo-avoidance during peak daytime ( P <0.001). CONCLUSION: There is a baseline disparity in knowledge related to PS and photo protection in CLE by race. A short educational intervention successfully improved immediate lupus-related PS and sun exposure knowledge, but knowledge was not retained long-term. It appears educational materials must be improved. J Drugs Dermatol. 2015;14(4):355-358.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):355-358.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The home beauty device market is rapidly growing, having more than tripled in the last four years. This study evaluates several specific attachment heads using a novel home skincare platform (HSP). By incorporating multiple treatment heads for cleansing, skin smoothing, and skin infusion, this device has the potential to address many potential treatment goals. The first subset of this study is a blinded, randomized split-face study evaluating the efficacy of the HSP device with a standard brush head for make-up removal and compares the HSP device to a currently marketed home cleansing device. The results show that the HSP cleansing head was comparable to the leading home skin cleansing device on the market. The HSP's skin smoothing head showed statistically significant improvement in erythema and dryness over baseline levels with significant histologic changes including normalization of epidermal thickness in only 10 days of use. This is comparable to and exceeds many well-studied antiaging treatments after weeks and months of therapy. Finally, the infusion head demonstrated improvement in skin hydration over baseline levels. J Drugs Dermatol. 2015;14(4):391-399.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):391-399.
  • Journal of drugs in dermatology: JDD 04/2015; 14(4):350-353.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The iPLEDGE protocol for isotretinoin treatment requires multiple steps to be completed within strict timing windows, resulting in many interruptions or discontinuations of treatment. The US Food and Drug Administration has indicated that approximately 40% of isotretinoin prescriptions written over the course of one year of the iPLEDGE program were denied due to failure to comply with iPLEDGE. Insurance restrictions add to the likelihood of prescriptions not being filled. Here, we describe a novel program implemented specifically to assist patients and providers with improving isotretinoin therapy adherence. This innovative isotretinoin support program provides assistance with insurance questions and hurdles, an uninterrupted treatment supply, educational support, reminder communications, and an indigent patient assistance program. Proof-of-concept analysis shows that 17 months after implementation of the program, 93% of prescriptions received have been filled. Utilization of the program appears to improve adherence to an isotretinoin treatment regimen, with fewer interruptions due directly to unfilled prescriptions. J Drugs Dermatol . 2015;14(4):375-379.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):375-379.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Under-eye bags are a common manifestation of age and a frequent complaint among patients who no longer feel youthful. Non-invasive topical agents are largely ineffective at reducing their appearance. OBJECTIVE: We studied the ability of a topical serum containing epidermal growth factor (EGF) to minimize the appearance of under-eye bags. METHODS: A single-center clinical trial was performed on eighteen volunteer male and female patients with under-eye bags. Subjects applied EGF serum to the infraorbital area twice daily for 12 weeks. At each visit, subjects were evaluated using clinical photography and written self-assessment. A grade on the Merz Infraorbital Hollowness Scale was also given and two independent, blind investigators assigned an Investigator's Global Assessment (IGA) score. At the trial's end, patients shared their final evaluation and perception of results with a questionnaire. RESULTS: Sixteen subjects completed the trial. The final average Merz grade was 1.63 (SEM = .273), statistically significantly lower than the mean baseline average of 2.06 (SEM = .232) ( P = .0019). A reduction in average IGA score was also significant ( P < .0001). Average initial IGA was 2.75 (SEM = .270) and average final IGA was 2.00 (SEM = .310). All but two subjects reported improvement at the final visit. Improvement was quantified as 76-100% by two subjects, 50-75% by three subjects, and 25-49% by nine subjects. Eleven subjects classified their under-eye bags as milder at the end of the trial compared to the first visit. Seven subjects reported greater satisfaction with their overall facial appearance. Of the subjects who had used other topical treatments in the past, two reported the serum to be "significantly better" and four said it was "better" in treating their under-eye bags. CONCLUSION: Our results offer evidence that topical EGF can reduce the appearance of under-eye bags. J Drugs Dermatol. 2015;14(4):405-410.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):405-410.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous Lupus Erythematosus (CLE) is a common manifestation in patients with Systemic Lupus Erythematosus. In a significant population of patients, CLE is the predominant feature and, in some cases, patients suffer from cutaneous disease alone. Chronic Cutaneous Lupus Erythematosus (CCLE) is a scarring subtype, more prevalent in blacks. Patients with skin of color may pose a challenge to physicians due to exaggerated cutaneous findings and increased risk of post-inflammatory hyperpigmentation and hypertrophic scarring. With the demographics of the United States rapidly shifting towards a greater population of non-Caucasian racial and ethnic groups, it is imperative that we expand on the limited research into molecular variation, clinical presentation, and therapeutic efficacy in CLE. The purpose of this review is to bring attention to the unique and severe aspects of CLE in persons of color, which calls for early and aggressive treatment. J Drugs Dermatol. 2015;14(4):343-349.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):343-349.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic exposure to the sun causes the skin to prematurely age. Photodamaged skin is characterized by progressive damage to the dermal extracellular matrix with loss of collagen and degradation of elastin. Clinical manifestations of such photoaged or photodamaged skin include wrinkles and irregular pigmentation. Various cosmetic treatments including topical retinoids, growth factors, and skin lighteners have shown some benefit. Salts of copper chlorophyllin complex are semi-synthetic naturally derived compounds with anti-oxidant and wound healing activity that has not been previously tested in photodamaged skin. OBJECTIVES: This single-center pilot study was conducted to assess the efficacy and safety of a liposomal dispersion of topically applied sodium copper chlorophyllin complex in women with mild-moderate fine lines and wrinkles in the periocular areas and facial solar lentigenes over a course of 8 weeks. METHODS: Subjects were supplied with the test product, a topical gel containing chlorophyllin complex salts (0.066%), with directions to apply a pea-sized amount to the periocular areas, cheeks and nose every morning and evening. Clinical assessments were performed at screening/baseline and at week 8. Standardized digital photographs were taken and self-assessment questionnaires were conducted. RESULTS: Ten subjects completed the 8-week study. All clinical efficacy parameters showed statistically significant improvements over baseline at week 8. The study product was well tolerated. Subject questionnaires showed the test product was highly rated. CONCLUSIONS: In this pilot study, a topical formulation containing a liposomal dispersion of sodium copper chlorophyllin complex was shown to be clinically effective and well tolerated for the treatment of mild-moderate photodamage and solar lentigenes when used for 8 weeks. J Drugs Dermatol . 2015;14(4):401-404.
    Journal of drugs in dermatology: JDD 04/2015; 14(4):401-404.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Q-switched lasers, such as the neodymium:yttrium-aluminum-garnet (Nd:YAG) laser, are the gold standard for tattoo removal. Allergy to tattoo pigment is well-documented, but adverse allergic reactions during or shortly after laser tattoo removal are rare with few reports in the medical literature. Here we describe an intraoperative, localized urticarial reaction that developed during treatment of a tattoo using a 1064-nm Nd:YAG laser. As laser tattoo removal becomes increasingly popular amongst our patients, it is important for dermatologists to be aware of urticarial allergic reactions as well as their management. We outline our recommendations for medical management of this condition and hope that these guidelines will facilitate patient care by dermatologists who encounter this immune skin reaction to laser tattoo removal. J Drugs Dermatol . 2015;14(3):303-304.
    Journal of drugs in dermatology: JDD 03/2015; 14(3):303-4.
  • Journal of drugs in dermatology: JDD 03/2015; 14(3):279-84.
  • Journal of drugs in dermatology: JDD 03/2015; 14(3):316-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advances in the understanding of the pathogenesis of psoriasis have led to the development of biologic agents that target T cells and cytokines that play a specific role in the underlying inflammation associated with psoriasis (eg, tumor necrosis factor-α inhibitors, interleukin [IL]-12/23 inhibitors). In this review, evidence for the central role of IL-17 in the pathophysiology of psoriasis is presented, along with available clinical trial data on the selective IL-17 inhibitors in development. Three biologic agents that target IL-17 are currently in clinical development: secukinumab, ixekizumab, and brodalumab. Clinical studies to date suggest a favorable safety profile and the potential for better efficacy over the previous generation of agents, with Psoriasis Area Severity Index 75 response rates of up to 80% or greater. Fully published results of phase III studies of these agents are eagerly awaited. J Drugs Dermatol. 2015;14(3):244-250.
    Journal of drugs in dermatology: JDD 03/2015; 14(3):244-50.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Various extracts of polypodium leucotomos (PLE) applied topically or taken orally have been shown to have several beneficial antioxidant, photoprotectant, antimutagenic, and immunoregulatory effects. Modern studies have evaluated the efficacy of PLE orally as a photoprotective agent and for use in several photo-aggravated dermatologic disorders such as polymorphous light eruption, other photodermatoses, and melasma. No articles have been published evaluating the safety of PLE. We performed a PUBMED search for any randomized clinical trials related to PLE, or anapsos, a synonym. The primary safety endpoint of the review was any mention of an adverse event, side effect, or toxicity. Overall, 19 human and 6 basic science studies were included spanning over 40 years of research. Oral PLE was administered at daily doses ranging from 120 mg to 1080 mg. No adverse effects were reported in laboratory studies. In humans, side effects (gastrointestinal complaints and pruritus) were mild to moderate and found only in very small numbers of patients overall (16/1016 [2%]). This review concludes PLE is well tolerated at all doses administered and associated with a negligible risk of side effects. J Drugs Dermatol . 2015;14(3):254-259.
    Journal of drugs in dermatology: JDD 03/2015; 14(3):254-9.